EGFR and ErbB2 are functionally coupled to CD44 and regulate shedding, internalization and motogenic effect of CD44

Cancer Letters

Volumn 263, Issue 2, 2008, Pages 231-242

  Pályi Krekk, Zsuzsanna ^a   Barok, Márk ^a   Kovács, Tamás ^a   Saya, Hideyuki ^b   Nagano, Osamu ^b   Szöllosi, János ^a,c   Nagy, Peter ^a  

^a UNIVERSITY OF DEBRECEN   (Hungary)

^b KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c UNIVERSITY OF DEBRECEN   (Hungary)

Author keywords

CD44 shedding; EGFR; ErbB2; Pertuzumab; Trastuzumab

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; HERMES ANTIGEN; HYALURONIC ACID; NEU DIFFERENTIATION FACTOR; OLIGOSACCHARIDE; PERTUZUMAB; TRASTUZUMAB;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HUMAN; HUMAN CELL; INTERNALIZATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD44; CELL LINE, TUMOR; CELL MOVEMENT; HUMANS; HYALURONIC ACID; MICE; MICE, SCID; NEOPLASM TRANSPLANTATION; NEUREGULIN-1; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2;

EID: 41649091787     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2008.01.014     Document Type: Article

References (55)

1. Holbro T., Civenni G., and Hynes N.E. The ErbB receptors and their role in cancer progression. Exp. Cell Res. 284 (2003) 99-110
2. Citri A., and Yarden Y. EGF-ERBB signalling: towards the systems level. Nat. Rev. Mol. Cell Biol. 7 (2006) 505-516
3. Yarden Y., and Sliwkowski M.X. Untangling the ErbB signalling network. Nat. Rev. Mol. Cell Biol. 2 (2001) 127-137
4. Klapper L.N., Glathe S., Vaisman N., Hynes N.E., Andrews G.C., Sela M., and Yarden Y. The ErbB-2/HER2 oncoprotein of human carcinomas may function solely as a shared coreceptor for multiple stroma-derived growth factors. Proc. Natl. Acad. Sci. USA 96 (1999) 4995-5000
5. Ohtsu H., Dempsey P.J., and Eguchi S. ADAMs as mediators of EGF receptor transactivation by G protein-coupled receptors. Am. J. Physiol. Cell Physiol. 291 (2006) C1-C10
6. Mocanu M.M., Fazekas Z., Petrás M., Nagy P., Sebestyén Z., Isola J., Tímár J., Park J.W., Vereb G., and Szöllo{combining double acute accent}si J. Associations of ErbB2 β1-integrin and lipid rafts on Herceptin (Trastuzumab) resistant and sensitive tumor cell lines. Cancer Lett. 227 (2005) 201-212
7. Ghatak S., Misra S., and Toole B.P. Hyaluronan constitutively regulates ErbB2 phosphorylation and signaling complex formation in carcinoma cells. J. Biol. Chem. 280 (2005) 8875-8883
8. Nagy P., Friedländer E., Tanner M., Kapanen A.I., Carraway K.L., Isola J., and Jovin T.M. Decreased accessibility and lack of activation of ErbB2 in JIMT-1, a herceptin-resistant, MUC4-expressing breast cancer cell line. Cancer Res. 65 (2005) 473-482
9. Ross J.S., Fletcher J.A., Linette G.P., Stec J., Clark E., Ayers M., Symmans W.F., Pusztai L., and Bloom K.J. The Her-2/neu gene and protein in breast cancer 2003: biomarker and target of therapy. Oncologist 8 (2003) 307-325
10. Mendelsohn J., and Baselga J. Epidermal growth factor receptor targeting in cancer. Semin. Oncol. 33 (2006) 369-385
11. Tokunaga E., Oki E., Nishida K., Koga T., Egashira A., Morita M., Kakeji Y., and Maehara Y. Trastuzumab and breast cancer: developments and current status. Int. J. Clin Oncol 11 (2006) 199-208
12. Reid A., Vidal L., Shaw H., and de Bono J. Dual inhibition of ErbB1 (EGFR/HER1) and ErbB2 (HER2/neu). Eur J Cancer 43 (2007) 481-489
13. Agus D.B., Akita R.W., Fox W.D., Lewis G.D., Higgins B., Pisacane P.I., Lofgren J.A., Tindell C., Evans D.P., Maiese K., Scher H.I., and Sliwkowski M.X. Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. Cancer Cell 2 (2002) 127-137
14. Barok M., Isola J., Pályi-Krekk Z., Nagy P., Juhász I., Vereb G., Kauraniemi P., Kapanen A., Tanner M., and Szöllo{combining double acute accent}si J. Trastuzumab causes antibody-dependent cellular cytotoxicity-mediated growth inhibition of submacroscopic JIMT-1 breast cancer xenografts despite intrinsic drug resistance. Mol. Cancer Ther. 6 (2007) 2065-2072
15. Clynes R.A., Towers T.L., Presta L.G., and Ravetch J.V. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat. Med. 6 (2000) 443-446
16. Nahta R., and Esteva F.J. Herceptin: mechanisms of action and resistance. Cancer Lett. 232 (2006) 123-138
17. Kono K., Takahashi A., Ichihara F., Sugai H., Fujii H., and Matsumoto Y. Impaired antibody-dependent cellular cytotoxicity mediated by herceptin in patients with gastric cancer. Cancer Res. 62 (2002) 5813-5817
18. Motoyama A.B., Hynes N.E., and Lane H.A. The efficacy of ErbB receptor-targeted anticancer therapeutics is influenced by the availability of epidermal growth factor-related peptides. Cancer Res. 62 (2002) 3151-3158
19. Ritter C.A., Perez-Torres M., Rinehart C., Guix M., Dugger T., Engelman J.A., and Arteaga C.L. Human breast cancer cells selected for resistance to trastuzumab in vivo overexpress epidermal growth factor receptor and ErbB ligands and remain dependent on the ErbB receptor network. Clin. Cancer Res. 13 (2007) 4909-4919
20. Pályi-Krekk Z., Barok M., Isola J., Tammi M., Szöllo{combining double acute accent}si J., and Nagy P. Hyaluronan-induced masking of ErbB2 and CD44-enhanced trastuzumab internalisation in trastuzumab resistant breast cancer. Eur. J. Cancer 43 (2007) 2423-2433
21. Turley E.A., Noble P.W., and Bourguignon L.Y. Signaling properties of hyaluronan receptors. J. Biol. Chem. 277 (2002) 4589-4592
22. Ghatak S., Misra S., and Toole B.P. Hyaluronan oligosaccharides inhibit anchorage-independent growth of tumor cells by suppressing the phosphoinositide 3-kinase/Akt cell survival pathway. J. Biol. Chem. 277 (2002) 38013-38020
23. Yu W.H., Woessner Jr. J.F., McNeish J.D., and Stamenkovic I. CD44 anchors the assembly of matrilysin/MMP-7 with heparin-binding epidermal growth factor precursor and ErbB4 and regulates female reproductive organ remodeling. Genes Dev. 16 (2002) 307-323
24. Bourguignon L.Y., Peyrollier K., Gilad E., and Brightman A. Hyaluronan-CD44 interaction with neural Wiskott-Aldrich syndrome protein (N-WASP) promotes actin polymerization and ErbB2 activation leading to beta-catenin nuclear translocation, transcriptional up-regulation, and cell migration in ovarian tumor cells. J. Biol Chem. 282 (2007) 1265-1280
25. Auvinen P., Tammi R., Tammi M., Johansson R., and Kosma V.M. Expression of CD44s, CD44v3 and CD44v6 in benign and malignant breast lesions: correlation and colocalization with hyaluronan. Histopathology 47 (2005) 420-428
26. Marhaba R., and Zoller M. CD44 in cancer progression: adhesion, migration and growth regulation. J. Mol. Histol. 35 (2004) 211-231
27. Auvinen P., Tammi R., Parkkinen J., Tammi M., Agren U., Johansson R., Hirvikoski P., Eskelinen M., and Kosma V.M. Hyaluronan in peritumoral stroma and malignant cells associates with breast cancer spreading and predicts survival. Am. J. Pathol. 156 (2000) 529-536
28. Peterson R.M., Yu Q., Stamenkovic I., and Toole B.P. Perturbation of hyaluronan interactions by soluble CD44 inhibits growth of murine mammary carcinoma cells in ascites. Am. J. Pathol. 156 (2000) 2159-2167
29. Nagano O., and Saya H. Mechanism and biological significance of CD44 cleavage. Cancer Sci. 95 (2004) 930-935
30. Toole B.P., Wight T.N., and Tammi M.I. Hyaluronan-cell interactions in cancer and vascular disease. J. Biol. Chem 277 (2002) 4593-4596
31. Liu D., Pearlman E., Diaconu E., Guo K., Mori H., Haqqi T., Markowitz S., Willson J., and Sy M.S. Expression of hyaluronidase by tumor cells induces angiogenesis in vivo. Proc. Natl. Acad. Sci. USA 93 (1996) 7832-7837
32. Kim R., Emi M., Tanabe K., and Arihiro K. Tumor-driven evolution of immunosuppressive networks during malignant progression. Cancer Res. 66 (2006) 5527-5536
33. Okamoto I., Kawano Y., Murakami D., Sasayama T., Araki N., Miki T., Wong A.J., and Saya H. Proteolytic release of CD44 intracellular domain and its role in the CD44 signaling pathway. J. Cell Biol. 155 (2001) 755-762
34. Sugahara K.N., Hirata T., Hayasaka H., Stern R., Murai T., and Miyasaka M. Tumor cells enhance their own CD44 cleavage and motility by generating hyaluronan fragments. J. Biol. Chem. 281 (2006) 5861-5868
35. Murai T., Miyauchi T., Yanagida T., and Sako Y. Epidermal growth factor-regulated activation of Rac GTPase enhances CD44 cleavage by metalloproteinase disintegrin ADAM10. Biochem. J. 395 (2006) 65-71
36. Yu Q., Toole B.P., and Stamenkovic I. Induction of apoptosis of metastatic mammary carcinoma cells in vivo by disruption of tumor cell surface CD44 function. J. Exp. Med. 186 (1997) 1985-1996
37. Guo Y.J., Liu G., Wang X., Jin D., Wu M., Ma J., and Sy M.S. Potential use of soluble CD44 in serum as indicator of tumor burden and metastasis in patients with gastric or colon cancer. Cancer Res. 54 (1994) 422-426
38. Ristamaki R., Joensuu H., Lappalainen K., Teerenhovi L., and Jalkanen S. Elevated serum CD44 level is associated with unfavorable outcome in non-Hodgkin's lymphoma. Blood 90 (1997) 4039-4045
39. Kopp R., Classen S., Wolf H., Gholam P., Possinger K., and Wilmanns W. Predictive relevance of soluble CD44v6 serum levels for the responsiveness to second line hormone- or chemotherapy in patients with metastatic breast cancer. Anticancer Res. 21 (2001) 2995-3000
40. Rio C., Buxbaum J.D., Peschon J.J., and Corfas G. Tumor necrosis factor-α-converting enzyme is required for cleavage of erbB4/HER4. J. Biol Chem. 275 (2000) 10379-10387
41. Lee H.J., Jung K.M., Huang Y.Z., Bennett L.B., Lee J.S., Mei L., and Kim T.W. Presenilin-dependent γ-secretase-like intramembrane cleavage of ErbB4. J. Biol Chem 277 (2002) 6318-6323
42. Molina M.A., Codony-Servat J., Albanell J., Rojo F., Arribas J., and Baselga J. Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells. Cancer Res 61 (2001) 4744-4749
43. Tanner M., Kapanen A.I., Junttila T., Raheem O., Grenman S., Elo J., Elenius K., and Isola J. Characterization of a novel cell line established from a patient with Herceptin-resistant breast cancer. Mol. Cancer Ther. 3 (2004) 1585-1592
44. Okamoto I., Kawano Y., Tsuiki H., Sasaki J., Nakao M., Matsumoto M., Suga M., Ando M., Nakajima M., and Saya H. CD44 cleavage induced by a membrane-associated metalloprotease plays a critical role in tumor cell migration. Oncogene 18 (1999) 1435-1446
45. Gonzalez R.C., Woods R.E., and Eddins S.L. Segmentation using the watershed algorithm. In: Gonzalez R.C., Woods R.E., and Eddins S.L. (Eds). Digital Image Processing Using Matlab (2004), Pearson Prentice Hall, Upper Saddle River 417-425
46. Liang C.C., Park A.Y., and Guan J.L. In vitro scratch assay: a convenient and inexpensive method for analysis of cell migration in vitro. Nat. Protoc. 2 (2007) 329-333
47. Kumar R. ErbB-dependent signaling as a determinant of trastuzumab resistance. Clin. Cancer Res. 13 (2007) 4657-4659
48. Feldner J.C., and Brandt B.H. Cancer cell motility--on the road from c-erbB-2 receptor steered signaling to actin reorganization. Exp. Cell Res. 272 (2002) 93-108
49. Tammi R., Rilla K., Pienimaki J.P., MacCallum D.K., Hogg M., Luukkonen M., Hascall V.C., and Tammi M. Hyaluronan enters keratinocytes by a novel endocytic route for catabolism. J. Biol. Chem. 276 (2001) 35111-35122
50. Laux I., Jain A., Singh S., and Agus D.B. Epidermal growth factor receptor dimerization status determines skin toxicity to HER-kinase targeted therapies. Br. J. Cancer 94 (2006) 85-92
51. Brockhoff G., Heckel B., Schmidt-Bruecken E., Plander M., Hofstaedter F., Vollmann A., and Diermeier S. Differential impact of Cetuximab Pertuzumab and Trastuzumab on BT474 and SK-BR-3 breast cancer cell proliferation. Cell Prolif. 40 (2007) 488-507
52. Misra S., Ghatak S., and Toole B.P. Regulation of MDR1 expression and drug resistance by a positive feedback loop involving hyaluronan, phosphoinositide 3-kinase, and ErbB2. J. Biol. Chem. 280 (2005) 20310-20315
53. Barok M., Balázs M., Nagy P., Rákosy Z., Treszl A., Tóth E., Juhász I., Park J.W., Isola J., Vereb G., and Szöllo{combining double acute accent}si J. Trastuzumab decreases the number of circulating and disseminated tumor cells despite trastuzumab resistance of the primary tumor. Cancer Lett. 260 (2008) 198-208
54. Ellis I.R., Schor A.M., and Schor S.L. EGF AND TGF-α motogenic activities are mediated by the EGF receptor via distinct matrix-dependent mechanisms. Exp. Cell Res. 313 (2007) 732-741
55. Camenisch T.D., Schroeder J.A., Bradley J., Klewer S.E., and McDonald J.A. Heart-valve mesenchyme formation is dependent on hyaluronan-augmented activation of ErbB2-ErbB3 receptors. Nat. Med. 8 (2002) 850-855